Lori L. Jensen

Oncology

4715 Arapahoe Ave
Boulder, CO 80303

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1 publications

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: June 18, 2019

Showing 1-1 of 1

Last Updated: 09/26/2026